Operating Expenses
Amgen·Income Statement·11 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total operating expenses | $6.5B | $6.5B | $6.8B | $7B | $6.5B | $7B | $7.1B | $6B |
| Research and development | $1.4B | $1.5B | $1.7B | $1.5B | $1.7B | $1.9B | $2.1B | $1.7B |
| Selling, general and administrative | $1.8B | $1.6B | $1.9B | $1.7B | $1.7B | $1.7B | $2B | $1.6B |
| Depreciation and amortization | $1.4B | $1.4B | $1.4B | $1.4B | $1.3B | $1.3B | $1.1B | $1.1B |
| Other nonrecurring (income) expense | — | — | — | $830M | — | — | — | -$113M |
| Stock-Based Compensation Expense | $157M | $136M | $134M | $85M | $157M | $127M | $125M | $75M |
| Share-Based Compensation Expense | $157M | $136M | $134M | $85M | $157M | $127M | $125M | $75M |
| Stock-based compensation expense | $157M | $136M | $134M | $85M | $157M | $127M | $125M | $75M |
| Share-Based Compensation | $157M | $136M | $134M | $85M | $157M | $127M | $125M | $75M |
| Impairment of Intangible Assets | $0 | $61M | $30M | $800M | — | $400M | — | $0 |
| Impairment of Intangible Assets (Excl. Goodwill) | $0 | $61M | $30M | $800M | — | $400M | — | $0 |